Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: abatacept
BRAND NAME: Orencia
DRUG CLASS AND MECHANISM: Abatacept is an injectable, synthetic (man-made) protein produced by recombinant DNA technology that is used for treating rheumatoid arthritis. It is an immunesuppressant, a drug that suppresses the immune system that is similar to alefacept (Amevive) and belatacept (Nulojix). The immune system is responsible for protecting the body against foreign invaders, for example, infectious agents such as bacteria. In patients with rheumatoid arthritis, however, the immune system attacks and destroys normal tissue in and around the joints, causing pain, inflammation and damage to bone and cartilage. T-lymphocytes are important cells of the immune system. Patients with rheumatoid arthritis have increased numbers of T-lymphocytes within the joints that are inflamed. The T-lymphocytes are "activated," that is, they multiply and release chemicals that promote the destruction of tissues surrounding the joints and cause the signs and symptoms of rheumatoid arthritis. Abatacept acts like an antibody and attaches to a protein on the surface of T-lymphocytes. By attaching to the protein, abatacept prevents the activation of the T-lymphocytes and blocks both the production of new T-lymphocytes and the production of the chemicals that destroy tissue and cause the symptoms and signs of arthritis. Abatacept relieves the symptoms and signs of arthritis and is a disease-modifying antirheumatic drug (DMARD) because it slows the damage to bones and cartilage and improves physical function. Abatacept was approved by the FDA in December 2005.
GENERIC AVAILABLE: No
PREPARATIONS: Powder for Injection: 250 mg. Prefilled Syringe: 125 mg/ml.
STORAGE: Abatacept should be refrigerated between 2-8 C (36-46 F).
PRESCRIBED FOR: Abatacept is used alone or in combination with other DMARDs for the treatment of adult patients with moderate to severe rheumatoid arthritis. It also is used alone or combined with methotrexate (Rheumatrex, Trexall) for treating juvenile idiopathic arthritis in pediatric patients 6 years of age or older. Abatacept should not be combined with the disease-modifying TNF antagonists (for example, etanercept [Enbrel], adalimumab [Humira] and infliximab [Remicade]).
DOSING: For adult patients, abatacept is infused over 30 minutes or injected under the skin. Patients weighing < 60 kg should receive a 500 mg dose, weighing 60-100 kg a 750 mg dose and weighing >100 kg a 1000 mg dose. The initial dose of abatacept is followed by additional doses two and four weeks after the first infusion with further doses every four weeks thereafter. Alternatively, adults may receive 125 mg by subcutaneous injection one day after the initial weight-based dose and then 125 mg by subcutaneous injection once weekly.
Patients 6 to 17 years old weighing less than 75 kg should receive a 10 mg/kg infusion initially. Pediatric patients weighing more than 75 kg should receive the adult infusion doses. The initial dose of abatacept is followed by additional doses two and four weeks after the first infusion with further doses every four weeks thereafter.
DRUG INTERACTIONS: Combining abatacept with TNF antagonists (for example, Enbrel, Humira and Remicade) increases the occurrence of infections and provides no additional relief of symptoms. Abatacept may reduce the effect of live vaccines. Live vaccines should not be given at the same time as abatacept or within three months of discontinuation of abatacept. Pediatric patients should receive all recommended immunizations prior to starting abatacept.
PREGNANCY: Abatacept has not been adequately evaluated in pregnant women.
NURSING MOTHERS: Abatacept has not been adequately evaluated in women who are breastfeeding.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index